Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
Singapore Inflation Stays Muted in May as Core CPI Misses Forecasts Ahead of MAS Review 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
